Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
March 29th 2025“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer," says Dr Louise Kostos.
What a long-term study of patients undergoing RARC reveals about upstaging
March 25th 2025“High risk, non–muscle invasive bladder cancer carries a significant risk of recurrence and progression. This emphasizes the need for careful patient selection, especially when we are considering bladder-sparing approaches," says Neeraja Tillu, MD.
Kate H. Kraft, MD, discusses pre-op tamsulosin use in pediatric patients undergoing URS
March 20th 2025"When we compared the 2 groups, those that received tamsulosin and those that did not, we did find a significant difference with regard to success rates," says Kate H. Kraft, MD, MHPE, FACS, FAAP. .
John P. Mulhall, MD, shares his reaction to the FDA’s testosterone labeling changes
March 19th 2025“In 5200 men, very clearly, definitively, irrefutably, it has been shown that testosterone therapy is not associated with MACE over the course of the 12 to 24 months after commencement of testosterone therapy," says John P. Mulhall, MD.
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer
March 17th 2025"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
PSMA PET and treatment intensification in mHSPC
March 13th 2025“The main challenge at the moment is patients are being diagnosed with metastatic disease far earlier than they would have been otherwise, and therefore [are being] considered for combination systemic therapy potentially years earlier than they would have been if we just looked at conventional imaging," says Dr Louise Kostos.
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
March 12th 2025"We need to be aware that patients have options for treatment of high-risk biochemical recurrence, and in order to identify that they have high-risk biochemical recurrence...we need to calculate PSA doubling time,” says Alicia Morgans, MD, MPH.
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
March 10th 2025"In terms of how I select patients, I really look at the timing of metastatic disease, so whether it's metachronous or synchronous and the volume, and I think at this stage, the data are most robust for the synchronous and high-volume patients," says Dr Louise Kostos.